Estriol

• UNSPSC Description:

  Estriol (Oestriol), an orally active estrogen, is a ERα and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects[1][2][3].

• Target Antigen:

  Endogenous Metabolite; Estrogen Receptor/ERR

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Estriol.html

• Purity:

  99.68

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C)

• Smiles:

  C[C@@]1([C@H]2O)[C@](C[C@H]2O)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1

• Molecular Weight:

  288.387

• References & Citations:

  [1]Rosamaria Lappano, et al. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol. 2010 May 14;320(1-2):162-70.|[2]Rainer Girgert, et al. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol. BMC Cancer. 2014 Dec 11:14:935. |[3]Aakifa Ahmad, et al. Proconvulsant effects of estriol, the third estrogen, in the mouse PTZ-kindling model. Neurol Sci. 2014 Oct;35(10):1561-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  50-27-1